Advertisement
New Zealand markets open in 9 hours 48 minutes
  • NZX 50

    11,946.43
    +143.15 (+1.21%)
     
  • NZD/USD

    0.5960
    +0.0023 (+0.39%)
     
  • NZD/EUR

    0.5558
    +0.0012 (+0.22%)
     
  • ALL ORDS

    7,937.50
    -0.40 (-0.01%)
     
  • ASX 200

    7,683.00
    -0.50 (-0.01%)
     
  • OIL

    83.04
    +0.23 (+0.28%)
     
  • GOLD

    2,341.10
    +2.70 (+0.12%)
     
  • NASDAQ

    17,526.80
    +55.33 (+0.32%)
     
  • FTSE

    8,096.77
    +56.39 (+0.70%)
     
  • Dow Jones

    38,460.92
    -42.77 (-0.11%)
     
  • DAX

    17,997.67
    -91.03 (-0.50%)
     
  • Hang Seng

    17,284.54
    +83.27 (+0.48%)
     
  • NIKKEI 225

    37,628.48
    -831.60 (-2.16%)
     
  • NZD/JPY

    92.6810
    +0.5660 (+0.61%)
     

Gilead Sciences Stock Has Only Done This in 1 of the Past 7 Years

Gilead Sciences Stock Has Only Done This in 1 of the Past 7 Years

Gilead Sciences (NASDAQ: GILD) has a bright future ahead with HIV treatment Sunlenca obtaining approval from the Food and Drug Administration last year and cancer drug Trodelvy continuing to show strong growth. Why has Gilead Sciences stock struggled? The simple reason for Gilead's woes is that the business has had trouble generating growth.